Welcome to our dedicated page for Verastem news (Ticker: $VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verastem's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verastem's position in the market.
Verastem Oncology (Nasdaq: VSTM) has begun a rolling submission of a New Drug Application (NDA) to the FDA for accelerated approval of the avutometinib and defactinib combination. This treatment is aimed at adult patients with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The submission will be completed in the second half of 2024 with mature data from the RAMP 201 trial, which shows promising response rates. Verastem plans to present this data at a medical conference and discuss potential approval paths for KRAS wild-type patients. The company will host an investor call on May 24, 2024, to provide updates.
Verastem Oncology (Nasdaq: VSTM) announced positive initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial for metastatic pancreatic cancer. The trial evaluates avutometinib plus defactinib combined with gemcitabine and Nab-paclitaxel. As of May 14, 2024, in dose level 1, 83% (5/6) of patients achieved a confirmed partial response. One dose-limiting toxicity was observed but later cleared. The results will be presented at the ASCO Annual Meeting on June 1, 2024. Verastem will host a conference call on May 24, 2024, to discuss these findings.
Verastem Oncology reported positive business updates, including FDA Fast Track Designations for multiple combination therapies in cancer treatment and plans for upcoming clinical data presentations. Financially, the company ended the first quarter of 2024 with $110.1 million in cash, but reported an increased net loss compared to the same period in 2023.
Verastem Oncology (VSTM) will present at the RBC Capital Markets Global Healthcare Conference, demonstrating commitment to advancing cancer treatments. The management team will participate in a fireside chat on May 14, 2024. The webcast can be accessed on the company's website.
